文献速递生殖医学产科

40岁以上女性改良自然周期与激素替代周期胚胎移植的回顾性分析

Modified natural cycle vs. hormone replacement therapy embryo transfer in women over 40 years old: a retrospective analysis.
PubMed 文献 · Fertil Steril · 2026-08-12

该多中心回顾性队列研究纳入西班牙和意大利21家诊所2019至2023年间16,579名40-49岁女性的26,039个单胚胎移植周期,比较改良自然周期(mNC-ET)与激素替代周期(HRT-ET)的活产率等结局。多因素分析显示两组活产率相当(aOR 1.11,95%CI 0.99-1.24),mNC-ET与较低临床流产风险(aOR 0.58,95%CI 0.46-0.73)和较高持续妊娠率(aOR 1.14,95%CI 1.02-1.26)相关。

要点

  • 40岁以上女性单胚胎移植中,mNC-ET与HRT-ET的活产率相当。
  • mNC-ET与较低临床流产风险及较高持续妊娠率相关。
  • 自体周期亚组中mNC-ET活产率更高(aOR 1.21,95%CI 1.02-1.44)。

核心结论

  • 在40岁以上女性中,改良自然周期胚胎移植的活产率与激素替代周期胚胎移植相当,支持其作为该人群子宫内膜准备方法的可行性。

研究设计与样本

  • 自体周期仅纳入整倍体冻胚移植,供卵周期纳入新鲜和冻胚移植。

主要发现

  • 多因素分析显示mNC-ET与HRT-ET的活产率相当(aOR 1.11,95%CI 0.99-1.24)。
  • mNC-ET与较低临床流产风险(aOR 0.58,95%CI 0.46-0.73)和较高持续妊娠率(aOR 1.14,95%CI 1.02-1.26)相关。
  • 自体周期亚组中,mNC-ET与较低临床流产风险(aOR 0.47,95%CI 0.32-0.68)、较高持续妊娠率(aOR 1.24,95%CI 1.05-1.47)和较高活产率(aOR 1.21,95%CI 1.02-1.44)相关。
  • 供卵周期中,mNC-ET与较低临床流产风险(aOR 0.66,95%CI 0.49-0.88)相关,活产率相当(aOR 1.06,95%CI 0.93-1.22)。

临床怎么用

  • 对于40岁以上接受单胚胎移植的女性,mNC-ET可作为HRT-ET的可行替代方案,尤其关注降低临床流产风险。

局限性

  • 回顾性观察性设计可能存在残余混杂。
  • 结论需进一步研究确认对生殖结局的影响及潜在产科获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare live birth rate (LBR) and other reproductive outcomes between modified natural cycle embryo transfer (mNC-ET) and hormone replacement therapy embryo transfer (HRT-ET) cycles in women aged ≥40 years undergoing single embryo transfer (SET). DESIGN: Observational, retrospective, multicentric cohort study. SUBJECTS: A total of 26,039 SETs performed in 16,579 women aged 40-49 years between January 2019 and December 2023 across 21 clinics in Spain and Italy. Only euploid frozen ETs were considered for autologous cycles, whereas both fresh and frozen ETs were included for egg donor cycles. EXPOSURE: Endometrial preparation with mNC-ET or HRT-ET protocols. MAIN OUTCOMES MEASURES: The primary outcome was LBR. Secondary outcomes included biochemical pregnancy rate (BPR), clinical pregnancy rate (CPR), and ongoing pregnancy rate (OPR), and biochemical miscarriage rate (BMR) and clinical miscarriage rate (CMR). RESULTS: The study analyzed 26,039 SETs (2,694 mNC-ETs vs. 23,345 HRT-ETs) in 16,579 patients (43.1 ± 2.4 years). Multivariate analysis adjusted for confounders demonstrated comparable LBR (adjusted odds ratio [aOR] 1.11, 95% confidence interval [CI]: 0.99-1.24) between mNC and HRT-ET, while mNC-ET was associated with lower risk of clinical miscarriage (aOR 0.58, 95% CI: 0.46-0.73) and higher OPR (aOR 1.14, 95% CI: 1.02-1.26). Subgroup analyses indicated that mNC-ET was associated with a lower risk of clinical miscarriage (aOR 0.47, 95% CI: 0.32-0.68) and a higher likelihood of OPR (aOR 1.24, 95% CI: 1.05-1.47) and live birth (aOR 1.21, 95% CI: 1.02-1.44) among autologous cycles. In donor oocyte cycles, it was associated with a reduced risk of clinical miscarriage (aOR 0.66, 95% CI: 0.49-0.88), and comparable live birth (aOR 1.06 , 95% CI: 0.93-1.22). CONCLUSION: Modified natural cycle embryo transfer was associated with a comparable LBR to that of HRT-ET in women over 40 years old, supporting its feasibility as an endometrial preparation method in this population. Further research should confirm the impact on reproductive outcomes and evaluate potential obstetric benefits in this population.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Molinaro P, Napoleoni E, Alonso-Mayo C, et al. Modified natural cycle vs. hormone replacement therapy embryo transfer in women over 40 years old: a retrospective analysis. Fertil Steril. 2026. PMID: 42586494. doi:10.1016/j.fertnstert.2026.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。